Systematic Review of Anluo Huaxian Pills Combined with Entecavir in the Treatment of Hepatitis B-related Liver Cirrhosis

ZHANG Yingxue; SUN Fengxia; LI Xiaoling

doi:10.14009/j.issn.1672-2124.2022.01.015

您当前的位置：

首页 >

文章列表页 >

Systematic Review of Anluo Huaxian Pills Combined with Entecavir in the Treatment of Hepatitis B-related Liver Cirrhosis

更新时间：2022-10-08

- Systematic Review of Anluo Huaxian Pills Combined with Entecavir in the Treatment of Hepatitis B-related Liver Cirrhosis
- Vol. 22, Issue 1, Pages: 70-76(2022)
- 作者机构：
  
  1. 首都医科大学附属北京中医医院感染科
  2. 北京中医药大学研究生院
- 作者简介：
- 基金信息：
- DOI：10.14009/j.issn.1672-2124.2022.01.015
  CLC： R512.62;R575.2
- Published：2022，
扫描看全文
ZHANG Yingxue, SUN Fengxia, LI Xiaoling. Systematic Review of Anluo Huaxian Pills Combined with Entecavir in the Treatment of Hepatitis B-related Liver Cirrhosis. [J]. 22(1):70-76(2022)
DOI：

ZHANG Yingxue, SUN Fengxia, LI Xiaoling. Systematic Review of Anluo Huaxian Pills Combined with Entecavir in the Treatment of Hepatitis B-related Liver Cirrhosis. [J]. 22(1):70-76(2022) DOI： 10.14009/j.issn.1672-2124.2022.01.015.

摘要

目的:系统评价安络化纤丸联合恩替卡韦改善乙型肝炎肝硬化患者肝纤维化及影像学指标的有效性及安全性。方法:检索中国知网、万方数据库、维普数据库、中国生物医学文献数据库、PubMed、Embase及the Cochrane Library

检索时间截至2021年11月6日

收集安络化纤丸联合恩替卡韦治疗乙型肝炎肝硬化的随机对照试验

采用Cochrane协作网的偏倚风险评估工具评价纳入研究的方法学质量

运用Rev Man 5.3软件进行数据合并。结果:纳入26篇符合标准的文献

共2 663例患者。Meta分析结果显示

安络化纤丸联合恩替卡韦治疗乙型肝炎肝硬化

在降低患者代偿期透明质酸(HA)水平(MD=-59.97

95%CI=-68.15～-51.79)、层粘连蛋白(LN)水平(MD=-62.20

95%CI=-78.15～-46.25)、Ⅳ型胶原蛋白(Ⅳ-C)水平(MD=-48.02

95%CI=-54.19～-41.85)以及失代偿期HA水平(MD=-145.04

95%CI=-154.92～-135.17)、LN水平(MD=-86.38

95%CI=-105.77～-66.98)、Ⅲ型前胶原水平(MD=-131.05

95%CI=-142.53～-119.56)、Ⅳ-C水平(MD=-108.22

95%CI=-122.49～-93.95)

缩小门静脉内径(MD=-0.07

95%CI=-0.14～-0.01)

缩小脾厚度(MD=-3.28

95%CI=-4.10～-2.46)

提高门静脉内径改善率(RR=1.55

95%CI=1.37～1.75)

提高脾静脉内径改善率(RR=1.77

95%CI=1.52～2.06)等方面均明显优于恩替卡韦单药治疗

差异均具有统计学意义(P<0.05)。结论:安络化纤丸联合恩替卡韦治疗乙型肝炎肝硬化

能更有效地降低患者肝纤维化水平

且能改善患者的门脉内径、脾厚度等影像学指标。但由于纳入研究质量低

样本量较少

上述结果仍需设计良好、大样本的随机对照试验进一步验证。

Abstract

OBJECTIVE: To systematically evaluate the efficacy and safety of Anluo Huaxian pills combined with entecavir in improving liver fibrosis and imaging indicators in patients with hepatitis B-related liver cirrhosis.METHODS: CNKI

Wanfang Data

VIP

CBM

PubMed

Embase and the Cochrane Library were retrieved to collect the randomized controlled trial of Anluo Huaxian pills combined with entecavir in the treatment of hepatitis B-related liver cirrhosis. The retrieval time was from the establishment of the database to Nov. 6 th

2021. The methodological quality of the included literature was evaluated by using the Cochrane bias risk assessment tool

and data were analyzed by using RevMan 5. 3 software. RESULTS: Totally 26 literature were enrolled

including 2 663 patients. Meta-analysis results showed that Anluo Huaxian pills combined with entecavir in the treatment of hepatitis B-related liver cirrhosis can reduce the hyaluronic acid（ HA） level during decorpesated period（ MD =-59. 97

95% CI =-68. 15--51. 79）

laminin（ LN） level（ MD =-62. 20

95%CI =-78. 15--46. 25）

type Ⅳ collagen（ Ⅳ-C） level（ MD =-48. 02

95% CI =-54. 19--41. 85） and HA level during decompensated period（ MD =-145. 04

95% CI =-154. 92--135. 17）

LN level（ MD =-86. 38

95% CI =-105. 77--66. 98）

type Ⅲ procollagen level（ MD =-131. 05

95% CI =-142. 53--119. 56）

Ⅳ-C level（ MD =-108. 22

95%CI =-122. 49--93. 95）

reduce the inner diameter of portal vein（ MD =-0. 07

95%CI =-0. 14--0. 01）

reduce the thickness of spleen（ MD =-3. 28

95%CI =-4. 10--2. 46）

increase the improvement rate of portal vein diameter（ RR = 1. 55

95% CI = 1. 37-1. 75）

and increase the improvement rate of splenic vein diameter（ RR = 1. 77

95% CI = 1. 52-2. 06） and other aspects were significantly better than entecavir monotherapy

and the differences were statistically significant（ P < 0. 05）. CONCLUSIONS: Anluo Huaxian pills combined with entecavir in the treatment of hepatitis B-related liver cirrhosis can more effectively reduce the level of liver fibrosis and improve the imaging indicators such as portal vein internal diameter and spleen thickness in patients.

关键词

安络化纤丸恩替卡韦乙型肝炎肝硬化Meta分析

Keywords

Anluo Huaxian pillsEntecavirHepatitis B-related liver cirrhosisMeta-analysis

references

查看原文

Views

141

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Systematic Evaluation of Biejiajian Pills Combined with Entecavir in the Treatment of Hepatitis B Cirrhosis

Systematic Review of Huisheng Oral Liquid on Coagulation Function, Efficacy and Safety of Patients with Non-Small Cell Lung Cancer

Systematic Review of Efficacy and Safety of Dantian Jiangzhi Pills Combined with Statins in the Treatment of Hyperlipidemia

Systematic Review of Clinical Efficacy and Safety of Formula Granules of Liangfu Pill in the Treatment of Epigastric Pain

Systematic Review of Runzao Zhiyang Capsules Combined with Antihistamine in the Treatment of Chronic Urticaria

Related Author

JIANG Yinxiao

XU Min

CHENG Huizhen

LIU Huan

PENG Xi

LI Haotian

WEI Shizhang

MA Xiao

Related Institution

School of Pharmacy,Chengdu University of Traditional Chinese Medicine,Key Laboratory of the Ministry of Education in China on the Standardization of Chinese Materia Medica

Dept.of Pharmacy,Fifth Medical Center of China PLA General Hospital

Dept. of Oncology, Jingmen First People’s Hospital

Traditional Chinese Medicine Phenomics Research Center, Traditional Chinese Medicine Hospital Affiliated to Southwest Medical University

Dept. of Internal Medicine of Traditional Chinese Medicine, Shanghai Seventh People’s Hospital

⁰